Day: January 6, 2022

Figure 1Response Rates at 3 Months-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months- -Once daily linzagolix 75 mg without ABT demonstrated statistically significant improvement for dysmenorrhea versus placebo and showed improvement but did not meet the co-primary objective of reduction in non-menstrual pelvic pain at 3 months; also showed improvement in secondary endpoints at 6 months- -Both doses of linzagolix were well-tolerated with minimal bone mineral...

Geneva, Switzerland, January 6 2022 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright BIOCONNECT Virtual Conference. In his presentation, which is scheduled for Monday, January 10, 2021 at 07:00 EST / 13:00 CET, Mr Dyer will provide a corporate update and discuss recent developments at Addex. A video of the presentation will be available for viewing on-demand by registered participants. Management will be available for virtual one-on-one meetings throughout the conference. For more information or to schedule a one-on-one meeting with management, please contact your conference representative or James@HaydenIR.com. About Addex Therapeutics:Addex Therapeutics is...

Pixium Vision to attend BIOMED EVENT®byInvest Securities on January 26, 2022 Paris, France, January 6, 2022 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today that Lloyd Diamond, Chief Executive Officer of Pixium Vision, will attend the BIOMED EVENT® by Invest Securities, being held on Wednesday, January 26, 2022. The BIOMED EVENT by Invest Securities will host a number of European listed biotech and healthcare companies and institutional investors. It will feature one-on-one meetings, group presentations and workshops. The event will take place at Salons Hoche, 9 Avenue Hoche, Paris, France. Those wishing to attend can register here. About Pixium Vision Pixium...

Saint Herblain (France), January 6, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the previously communicated timelines of its clinical trials and regulatory submissions for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. As announced in December 20211, the Company commenced rolling submissions for initial approval of VLA2001 with the European Medicines Agency, the UK MHRA and the Bahraini NHRA, and is continuing to work closely with those authorities to complete their review process following its positive Phase 3 trial results2. Valneva continues to expect potential regulatory approvals in the first quarter of 20221. The Company also announced positive homologous booster results at the end of December 20213. The data showed an excellent immune response after a third...

Issy-les-Moulineaux, January 6, 2022Sodexo (NYSE Euronext Paris FR 0000121220-OTC: SDXAY).Organic revenue growth +17.5% Activity back up to 95% of pre-Covid levels Good control of inflation during the quarterQ1 Fiscal 2022 revenuesREVENUES(in millions of euro) Q1 FY22 Q1 FY21   RESTATEDORGANIC GROWTH   ORGANIC GROWTH EXTERNAL GROWTH CURRENCY EFFECT TOTAL GROWTHBusiness & Administrations 2,617    2,185      +19.5 %   +19.6 % -2.0 % +2.1 % +19.8 %Healthcare & Seniors 1,339    1,161      +7.4 %   +12.3 % +0.7 % +2.3 % +15.3 %Education 1,126    918      +28.7 %   +21.0 % -0.4 % +2.1...

London, United Kingdom, Jan. 06, 2022 (GLOBE NEWSWIRE) — Rapid Nutrition PLC (Euronext Growth: ALRPD, OTCQB: RPNRF), a natural healthcare company focused on sports nutrition, diet management and life sciences products continues to increase its worldwide distribution, with the expansion of its global distribution of its organic health and wellness products SystemLS throughout South Korea with the support of new partner SM Trading, a division of Ilshin World Corporation. This announcement follows on the heels of the company’s recent distribution agreement with Zone Eight forming part of the RKSB Group in Saudi Arabia last month. With its focus on serving as the leading distributor of imported products to South Korea, Ilshin’s company-owned warehouses enable top-notch logistics and distribution. Established in 2000, Ilshin exclusively...

Vancouver, B.C., Jan. 05, 2022 (GLOBE NEWSWIRE) — Muzhu Mining Ltd. (CSE: MUZU) (“Muzhu” or the “Company”) announces it has granted incentive stock options to certain directors, officers and consultants of the Company to acquire an aggregate of 1,330,000 common shares in the capital of the company at an exercise price of $0.14 cents (the “options”) in accordance with the Company’s 10% rolling incentive stock option plan. The options are exercisable for a five-year term expiring January 5th, 2027. Muzhu Mining Ltd. is a Canadian junior exploration company currently operating in Quebec. Muzhu currently holds a 100% interest in the Sleeping Giant South Project, located in the Abitibi Greenstone Belt, approximately 75km South of Matagami, Quebec of which Hwy. #109 runs through. ON BEHALF OF THE BOARD OF DIRECTORS Donald Baxter, P....